Denmark's BioPorto Q4 revenue rises on NGAL sales

Reuters

Feb 06

Denmark's BioPorto Q4 revenue rises on NGAL sales

Overview

Denmark in vitro diagnostics firm's Q4 2025 revenue rose 47% yr/yr, driven by NGAL sales
Company's FY 2025 revenue grew 11%, within guidance range of DKK 40-45 mln
Adjusted EBITDA loss for FY 2025 was within guidance, estimated at app. DKK 77 mln

Outlook

BioPorto targets 2026 total revenue of DKK 48-58 mln, up 20-45%
Company expects 2026 NGAL revenue to grow 20-50%
BioPorto forecasts 2026 adjusted EBITDA loss of DKK 50-60 mln, a 22-35% decrease

Result Drivers

NGAL SALES - Strong Q4 revenue growth driven by NGAL sales, particularly in the U.S. and strategic distributors
STRATEGIC DISTRIBUTORS - Revenue boost from large bulk order to strategic distributor in Q4
U.S. MARKET ADOPTION - Increased NGAL RUO sales in the U.S. contributed to revenue growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue		DKK 11.6 mln
Q4 Adjusted EBITDA		DKK 13.7 mln

Press Release: ID:nGNE8ddzFG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609842589"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609842589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609842589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 04:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609842589","market":"fut","top_or_hot":-1,"title":"Denmark's BioPorto Q4 revenue rises on NGAL sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Denmark's BioPorto Q4 revenue rises on NGAL sales</title></head><body><p><span>Overview</span></p><ul><li><p>Denmark in vitro diagnostics firm's Q4 2025 revenue rose 47% yr/yr, driven by NGAL sales</p></li><li><p>Company's FY 2025 revenue grew 11%, within guidance range of DKK 40-45 mln</p></li><li><p>Adjusted EBITDA loss for FY 2025 was within guidance, estimated at app. DKK 77 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>BioPorto targets 2026 total revenue of DKK 48-58 mln, up 20-45%</p></li><li><p>Company expects 2026 NGAL revenue to grow 20-50%</p></li><li><p>BioPorto forecasts 2026 adjusted EBITDA loss of DKK 50-60 mln, a 22-35% decrease</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NGAL SALES - Strong Q4 revenue growth driven by NGAL sales, particularly in the U.S. and strategic distributors</p></li><li><p>STRATEGIC DISTRIBUTORS - Revenue boost from large bulk order to strategic distributor in Q4</p></li><li><p>U.S. MARKET ADOPTION - Increased NGAL RUO sales in the U.S. contributed to revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>DKK 11.6 mln</p></td><td></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td></td><td><p>DKK 13.7 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNE8ddzFG</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denmark's BioPorto Q4 revenue rises on NGAL sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenmark's BioPorto Q4 revenue rises on NGAL sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 04:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Denmark's BioPorto Q4 revenue rises on NGAL sales</title></head><body><p><span>Overview</span></p><ul><li><p>Denmark in vitro diagnostics firm's Q4 2025 revenue rose 47% yr/yr, driven by NGAL sales</p></li><li><p>Company's FY 2025 revenue grew 11%, within guidance range of DKK 40-45 mln</p></li><li><p>Adjusted EBITDA loss for FY 2025 was within guidance, estimated at app. DKK 77 mln</p></li></ul><p><span>Outlook</span></p><ul><li><p>BioPorto targets 2026 total revenue of DKK 48-58 mln, up 20-45%</p></li><li><p>Company expects 2026 NGAL revenue to grow 20-50%</p></li><li><p>BioPorto forecasts 2026 adjusted EBITDA loss of DKK 50-60 mln, a 22-35% decrease</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NGAL SALES - Strong Q4 revenue growth driven by NGAL sales, particularly in the U.S. and strategic distributors</p></li><li><p>STRATEGIC DISTRIBUTORS - Revenue boost from large bulk order to strategic distributor in Q4</p></li><li><p>U.S. MARKET ADOPTION - Increased NGAL RUO sales in the U.S. contributed to revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td></td><td><p>DKK 11.6 mln</p></td><td></td></tr><tr><td><p>Q4 Adjusted EBITDA</p></td><td></td><td><p>DKK 13.7 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNE8ddzFG</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMI","symbol_name":"康明斯","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nL1N3Z11EF:1","article_id":"2609842589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609842589","pubTimestamp":1770322200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Denmark's BioPorto Q4 revenue rises on NGAL salesOverviewDenmark in vitro diagnostics firm's Q4 2025 revenue rose 47% yr/yr, driven by NGAL salesCompany's FY 2025 revenue grew 11%, within guidance ran","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMI":"康明斯","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","BK4588":"碎股","BK4149":"建筑机械与重型卡车","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV"},"translate_title":"丹麦BioPorto第四季度收入因NGAL销售而增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9},"content_text":"Denmark's BioPorto Q4 revenue rises on NGAL salesOverviewDenmark in vitro diagnostics firm's Q4 2025 revenue rose 47% yr/yr, driven by NGAL salesCompany's FY 2025 revenue grew 11%, within guidance range of DKK 40-45 mlnAdjusted EBITDA loss for FY 2025 was within guidance, estimated at app. DKK 77 mlnOutlookBioPorto targets 2026 total revenue of DKK 48-58 mln, up 20-45%Company expects 2026 NGAL revenue to grow 20-50%BioPorto forecasts 2026 adjusted EBITDA loss of DKK 50-60 mln, a 22-35% decreaseResult DriversNGAL SALES - Strong Q4 revenue growth driven by NGAL sales, particularly in the U.S. and strategic distributorsSTRATEGIC DISTRIBUTORS - Revenue boost from large bulk order to strategic distributor in Q4U.S. MARKET ADOPTION - Increased NGAL RUO sales in the U.S. contributed to revenue growthKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueDKK 11.6 mlnQ4 Adjusted EBITDADKK 13.7 mlnPress Release: ID:nGNE8ddzFGFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}